A. Kis

Beyond animal models: using human pluripotent stem cell-derived stem and progenitor cells to predict cytotoxicity in normal tissues

Background The clinical efficacy of anticancer drugs is often limited by dose-dependent toxicity to normal cells, particularly to rapidly dividing stem and progenitor cell populations. Traditional preclinical toxicity screening relies on animal models or primary human cells/immortalized lines, both of which have signif...